Defunct Company
Total Trials
9
As Lead Sponsor
As Collaborator
0
Total Enrollment
535
NCT00363974
Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML
Phase: Phase 1/2
Role: Lead Sponsor
Start: Oct 31, 2005
Completion: Mar 31, 2009
NCT00385775
Study of XIAP Antisense for Advanced Cancers
Phase: Phase 1
Start: Jun 30, 2006
Completion: Nov 30, 2008
NCT00557596
A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer
Start: Sep 30, 2007
Completion: Nov 30, 2009
NCT00558922
A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
Completion: Oct 31, 2009
NCT00558545
A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer
Start: Nov 30, 2007
Completion: May 31, 2009
NCT00768339
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Start: Sep 30, 2008
Completion: Sep 30, 2011
NCT00882869
XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Start: Mar 31, 2009
Completion: May 31, 2011
NCT00891683
Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy
Phase: Phase 2
Completion: Feb 28, 2010
NCT01018069
AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen
Start: Nov 30, 2009
Completion: Oct 31, 2010